Dis-CoV-er

  • Research type

    Research Study

  • Full title

    Dis-CoV-er: Developing a COVID-19 risk stratification tool for cancer patients based on an investigation of SARS-CoV-2 exposure and handling.

  • IRAS ID

    285060

  • Contact name

    Nagesh Kalakonda

  • Contact email

    nageshk@liverpool.ac.uk

  • Sponsor organisation

    Clatterbridge Cancer Centre

  • Duration of Study in the UK

    1 years, 2 months, 0 days

  • Research summary

    Research Summary
    The emergence and establishment of the COVID-19 pandemic and ‘social-distancing’ and ‘travel restriction’ measures are impacting delivery of cancer care, treatment decisions and outcomes. To understand the true impact of the pandemic a more comprehensive testing strategy 1) to establish infection rates and 2) assessment of immunological responses to viral exposure is essential.
    Patients attending hospitals (CCC and CH) for essential inpatient, outpatient, day care or treatment episodes whose SARS-CoV-2 infection status is unknown or previously negative will be invited to participate in this study. Viral swabs and blood samples will be obtained at presentation and after an interval. The samples will be biobanked and analysed at the end of the recruitment period (1000 patients; 6 – 10 weeks). Consent will be sought for access to anonymised demographic and clinical data to draw conclusions regarding exposure, susceptibility, and immune responses to SARS-CoV-2 and associated risk factors.

    Summary of Results
    No Lay Summary of results has been prepared

  • REC name

    East of England - Essex Research Ethics Committee

  • REC reference

    20/EE/0171

  • Date of REC Opinion

    22 Jul 2020

  • REC opinion

    Further Information Favourable Opinion